Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 3 boards, counting each seat separately. Longest: Enliven Therapeutics Inc., 3 years.
Enliven Therapeutics Inc.
Director
Immunovant Inc.
Director
BridgeBio Oncology Therapeutics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Immunovant Inc. August 27, 202594.9%
-
BridgeBio Oncology Therapeutics Inc. August 4, 2025100.0%
-
Enliven Therapeutics Inc. June 24, 202599.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 7, 2026 | Immunovant Inc. | Grant or award | +13,880 | — | — |
| May 1, 2025 | Immunovant Inc. | Grant or award | +25,016 | — | — |
| Feb 23, 2023 | Enliven Therapeutics Inc. | Grant or award | +87,372 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.